BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014;40:171-7. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Li X, Zhu Y, Ge R. Molecular Mechanisms of Bismuth-containing Drugs Against Helicobacter pylori: a Further Update. Curr Pharmacol Rep 2022. [DOI: 10.1007/s40495-022-00305-9] [Reference Citation Analysis]
2 Lee TH, Jeong HY, An DY, Kim H, Cho JY, Hwang DY, Lee HJ, Ham KS, Moon JH. Bamboo Salt and Triple Therapy Synergistically Inhibit Helicobacter pylori-Induced Gastritis In Vivo: A Preliminary Study. Int J Mol Sci 2022;23. [PMID: 36430475 DOI: 10.3390/ijms232213997] [Reference Citation Analysis]
3 Correia C, Almeida N, Leal C, Branquinho D, Fernandes A, Gravito-Soares E, Calhau C, Bastos I, Vasconcelos H, Figueiredo P. Single-capsule bismuth-based quadruple therapy as a rescue therapy for Helicobacter pylori eradication. Scand J Gastroenterol 2022;:1-5. [PMID: 36189844 DOI: 10.1080/00365521.2022.2119097] [Reference Citation Analysis]
4 Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022:gutjnl-2022-327745. [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 28.0] [Reference Citation Analysis]
5 Bi H, Chen X, Chen Y, Zhao X, Wang S, Wang J, Lyu T, Han S, Lin T, Li M, Yuan D, Liu J, Shi Y. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. Chin Med J (Engl) 2022;135:1707-15. [PMID: 36193978 DOI: 10.1097/CM9.0000000000002289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wasielica-berger J, Gugnacki P, Mlynarczyk M, Rogalski P, Swidnicka-siergiejko A, Antonowicz S, Krzyzak M, Maslach D, Dabrowski A, Daniluk J. Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. IJERPH 2022;19:6921. [DOI: 10.3390/ijerph19116921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 De Francesco V, Zullo A, Manta R, Gatta L, Fiorini G, Saracino IM, Vaira D. Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review. Eur J Gastroenterol Hepatol 2021;33:e66-70. [PMID: 33741798 DOI: 10.1097/MEG.0000000000002100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Pellicano R, Ribaldone DG, Caviglia GP. Strategies for Helicobacter pylori eradication in the year 2020. Saudi J Gastroenterol 2020;26:63-5. [PMID: 32295934 DOI: 10.4103/sjg.SJG_95_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Jeong HY, Lee TH, Kim JG, Lee S, Moon C, Truong XT, Jeon TI, Moon JH. 3-Pentylcatechol, a Non-Allergenic Urushiol Derivative, Displays Anti-Helicobacter pylori Activity In Vivo. Pharmaceuticals (Basel) 2020;13:E384. [PMID: 33202739 DOI: 10.3390/ph13110384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
12 Kim JY, Lee SY, Kim JH, Sung IK, Park HS. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Helicobacter 2020;25:e12683. [PMID: 32074663 DOI: 10.1111/hel.12683] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
13 Fong IW. Helicobacter pylori Infection: When Should It Be Treated? Current Trends and Concerns in Infectious Diseases 2020. [DOI: 10.1007/978-3-030-36966-8_4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wang R, Li H, Ip TK, Sun H. Bismuth drugs as antimicrobial agents. Medicinal Chemistry 2020. [DOI: 10.1016/bs.adioch.2019.10.011] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Farzi N, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Marian Smith S, Raymond J, Suzuki H, Zali MR. High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. J Clin Med. 2019;8. [PMID: 31744181 DOI: 10.3390/jcm8112004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
16 Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019;24:e12606. [PMID: 31168941 DOI: 10.1111/hel.12606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
18 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:666-72. [PMID: 30726563 DOI: 10.1111/jgh.14625] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
19 Eleje GU, Ogbunugafor HA, Emegoakor CD, Okoye EI, Ezejiofor OI, Chukwurah SN, Ikechebelu JI, Nchinda GW, Ugochukwu CG, Nnaji-Ihedinmah LI, Okoye FBC, Eneh FU, Onwukamuche ME, Esimone CO. Efficacy and safety of Syferol-IHP for the treatment of peptic ulcer disease: a pilot, double-blind randomized trial. Clin Exp Gastroenterol 2019;12:21-30. [PMID: 30679917 DOI: 10.2147/CEG.S178179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy. Korean J Gastroenterol 2019;73:26. [DOI: 10.4166/kjg.2019.73.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Agudo-fernández S, González Blanco A. Retrospective analysis of the use of quadruple therapy with bismuth (Pylera®) in real-life clinical practice in Spain. Gastroenterología y Hepatología (English Edition) 2018;41:483-489. [DOI: 10.1016/j.gastre.2018.05.017] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Agudo-fernández S, González Blanco A. Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera®) en la práctica clínica real en España. Gastroenterología y Hepatología 2018;41:483-9. [DOI: 10.1016/j.gastrohep.2018.05.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
23 Zagari RM, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, Savarino E, Maconi G, Stasi E, Eusebi LH, Farinati F, Conigliaro R, Bazzoli F, Romano M. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. Helicobacter 2018;23:e12502. [PMID: 29924430 DOI: 10.1111/hel.12502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
24 Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PLoS One 2018;13:e0197096. [PMID: 29889843 DOI: 10.1371/journal.pone.0197096] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
25 Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Scida S, Miraglia C, Penna A, Licci C, Rizzo GL, Pranzo G, Cassieri C, Brandimarte G, Picchio M, Di Mario F. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. Dig Dis 2018;36:264-8. [PMID: 29669354 DOI: 10.1159/000487391] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
26 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
27 Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018;73:1681-7. [DOI: 10.1093/jac/dky056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
28 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. Gastroenterología y Hepatología (English Edition) 2018;41:145-152. [DOI: 10.1016/j.gastre.2018.03.004] [Reference Citation Analysis]
29 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
30 Mantegazza C, Molinari P, D’auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacological Research 2018;128:63-72. [DOI: 10.1016/j.phrs.2017.08.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 13.4] [Reference Citation Analysis]
31 Ramírez FB, Núñez CG, Tejero Mas M, Rivera Jiménez N, Pérez Caballero FL. Criterios para la erradicación de Helicobacter pylori. FMC - Formación Médica Continuada en Atención Primaria 2018;25:43-53. [DOI: 10.1016/j.fmc.2017.03.009] [Reference Citation Analysis]
32 Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017;22. [PMID: 28833925 DOI: 10.1111/hel.12429] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
33 Fiorini G, Saracino IM, Zullo A, Gatta L, Pavoni M, Vaira D. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains. Helicobacter 2017;22. [PMID: 29094477 DOI: 10.1111/hel.12448] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
34 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera(®) ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22. [PMID: 28771880 DOI: 10.1111/hel.12423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
35 Vega-Jiménez AL, Almaguer-Flores A, Flores-Castañeda M, Camps E, Uribe-Ramírez M, Aztatzi-Aguilar OG, De Vizcaya-Ruiz A. Bismuth subsalicylate nanoparticles with anaerobic antibacterial activity for dental applications. Nanotechnology 2017;28:435101. [PMID: 28837052 DOI: 10.1088/1361-6528/aa8838] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
36 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
37 Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017;11:2209-20. [PMID: 28814829 DOI: 10.2147/DDDT.S136240] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
38 Sapmaz F, Kalkan IH, Atasoy P, Basyigit S, Guliter S. A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. American Journal of Therapeutics 2017;24:e393-8. [DOI: 10.1097/mjt.0000000000000316] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
39 Lyseng-williamson KA. Pylera® (bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride) in the eradication of Helicobacter pylori infection: a profile of its use in Europe. Drugs Ther Perspect 2017;33:311-320. [DOI: 10.1007/s40267-017-0417-7] [Reference Citation Analysis]
40 Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M; ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991-1003. [PMID: 28541262 DOI: 10.1097/MPG.0000000000001594] [Cited by in Crossref: 220] [Cited by in F6Publishing: 209] [Article Influence: 36.7] [Reference Citation Analysis]
41 Tursi A, Di Mario F, Franceschi M, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Grillo S, Landi S, Zamparella M, De Polo M, Boscariolo L, Picchio M. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. Helicobacter 2017;22. [PMID: 28125857 DOI: 10.1111/hel.12371] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
42 Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P, Megraud F, Nugent S, O'Connor A, O'Morain C, Weston S, McNamara D. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol 2017;29:552-9. [PMID: 28350745 DOI: 10.1097/MEG.0000000000000822] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
43 Harmati M, Gyukity-Sebestyen E, Dobra G, Terhes G, Urban E, Decsi G, Mimica-Dukić N, Lesjak M, Simin N, Pap B, Nemeth IB, Buzas K. Binary mixture of Satureja hortensis and Origanum vulgare subsp. hirtum essential oils: in vivo therapeutic efficiency against Helicobacter pylori infection. Helicobacter 2017;22. [PMID: 27578489 DOI: 10.1111/hel.12350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
44 Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
45 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
46 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1634] [Cited by in F6Publishing: 1490] [Article Influence: 272.3] [Reference Citation Analysis]
47 Mao F, Wen L, Sun C, Zhang S, Wang G, Zeng J, Wang Y, Ma J, Gao M, Li Z. Ultrasmall Biocompatible Bi2Se3 Nanodots for Multimodal Imaging-Guided Synergistic Radiophotothermal Therapy against Cancer. ACS Nano 2016;10:11145-55. [PMID: 28024338 DOI: 10.1021/acsnano.6b06067] [Cited by in Crossref: 164] [Cited by in F6Publishing: 168] [Article Influence: 23.4] [Reference Citation Analysis]
48 Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. Am J Gastroenterol 2016;111:1736-42. [PMID: 27670603 DOI: 10.1038/ajg.2016.443] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
49 Gisbert JP, Molina-infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-fernández M, Cuadrado-lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-aisa Á, Pérez-trallero E, Mcnicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2016;39:697-721. [DOI: 10.1016/j.gastre.2016.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Muller N, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier JC. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol 2016;40:517-24. [PMID: 26850363 DOI: 10.1016/j.clinre.2015.12.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
51 Marshall BJ. Helicobacter Pylori. Practical Gastroenterology and Hepatology Board Review Toolkit 2016. [DOI: 10.1002/9781119127437.ch19] [Reference Citation Analysis]
52 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 11.1] [Reference Citation Analysis]
53 Shaikh T, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. Can J Gastroenterol Hepatol 2016;2016:7321574. [PMID: 27446864 DOI: 10.1155/2016/7321574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol 2016; 22(11): 3150-3157 [PMID: 27003991 DOI: 10.3748/wjg.v22.i11.3150] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
55 Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases 2016; 4(1): 5-19 [PMID: 26798626 DOI: 10.12998/wjcc.v4.i1.5] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 90] [Article Influence: 12.6] [Reference Citation Analysis]
56 Molina-infante J. Quadruple Regimens for Helicobacter pylori Infection. Helicobacter pylori 2016. [DOI: 10.1007/978-4-431-55705-0_15] [Reference Citation Analysis]
57 McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016;4:546-561. [PMID: 27536365 DOI: 10.1177/2050640615617358] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 9.4] [Reference Citation Analysis]
58 Flores-castañeda M, Vega-jiménez AL, Almaguer-flores A, Camps E, Pérez M, Silva-bermudez P, Berea E, Rodil SE. Antibacterial effect of bismuth subsalicylate nanoparticles synthesized by laser ablation. J Nanopart Res 2015;17. [DOI: 10.1007/s11051-015-3237-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
59 Graham DY, Lee SY. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am 2015;44:537-63. [PMID: 26314667 DOI: 10.1016/j.gtc.2015.05.003] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 11.3] [Reference Citation Analysis]
60 O'Connor A, Gisbert JP, O'Morain C, Ladas S. Treatment of Helicobacter pylori Infection 2015. Helicobacter 2015;20 Suppl 1:54-61. [PMID: 26372826 DOI: 10.1111/hel.12258] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
61 Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am 2015;44:519-35. [PMID: 26314666 DOI: 10.1016/j.gtc.2015.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
62 Aktaş B, Başyiğit S, Yüksel O, Akkan T, Atbaşı ST, Uzman M, Yılmaz B, Şimşek G, Nazlıgül Y. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. Eur J Gastroenterol Hepatol 2015;27:769-75. [PMID: 25919773 DOI: 10.1097/MEG.0000000000000372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
63 Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol 2015; 21(21): 6698-6705 [PMID: 26074708 DOI: 10.3748/wjg.v21.i21.6698] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
64 Esquivel-gaon M, Anguissola S, Garry D, Gallegos-melgar ADC, Saldaña JM, Dawson KA, De Vizcaya-ruiz A, Del Razo LM. Bismuth-based nanoparticles as the environmentally friendly replacement for lead-based piezoelectrics. RSC Adv 2015;5:27295-304. [DOI: 10.1039/c5ra02151k] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
65 Malfertheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol 2014;30:589-95. [PMID: 25268839 DOI: 10.1097/MOG.0000000000000128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
66 [DOI: 10.1101/569814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]